Chen Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Chen Wang has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Olivier Lichtarge
Baylor College of Medicine, Houston, TX USA
7 shared publications - David C. Marciano
Baylor College of Medicine
4 shared publications - Bing-Hao Luo
Department of Life Science University of Louisiana State University Baton Rouge Louisiana USA
3 shared publications - Panagiotis Katsonis
Department of Molecular and Human Genetics, Baylor College of Medicine
3 shared publications Brent C. Christner
Department of Biological Sciences, Louisiana State University, Baton Rouge, Louisiana, United States of America
2 shared publications- Christophe Herman
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, USA
2 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (46)
Phylogenetic profiling reveals evolutionary coupling between methyltransferases and the cytoskeleton
Methylation is a fundamental post-translational modification best understood as regulating chromatin structure and gene expression, yet there is emerging evidence that methylation also shapes cytoskeletal organization, regulating key processes such as mitosis and cell migration. Proteomic studies have revealed cytoskeletal protein methylation is widespread, however little is known about the enzymes responsible for these modifications, or their evolutionary relationship to other, better known substrates for methylation, such as chromatin. To address this question, we applied phylogenetic profiling across the complete repertoire of human methyltransferases to identify conserved functional relationships extending beyond chromatin. Unbiased clustering revealed extensive coevolution between methyltransferases and many components of the cytoskeleton, uncovering a previously unrecognized evolutionary network linking canonical chromatin regulatory enzymes to cellular structural systems. Evolutionary Trace analysis of the H3K36 methyltransferase family recovered known catalytic and regulatory domains while identifying additional evolutionarily constrained residues, suggesting previously unappreciated functional interfaces. Comparative analyses further distinguished deeply conserved methyltransferase–cytoskeletal relationships from those that emerged later during eukaryotic evolution, indicating that cytoskeletal methylation comprises both ancient and lineage-expanded regulatory programs. Leveraging these evolutionary signatures, we identified and experimentally validated a previously unrecognized association between the methyltransferase NSD3 and α-tubulin. Together, these findings reveal that methyltransferases traditionally viewed as chromatin regulators participate in an evolutionarily conserved network that coordinates nuclear and cytoskeletal functions. More broadly, they establish phylogenetic profiling as a powerful approach for discovering noncanonical activities of chromatin-associated enzymes and suggest that regulation of chromatin organization and cellular architecture evolved as interconnected processes.
- 11 November 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (46)
Open AccessPhylogenetic profiling reveals evolutionary coupling between methyltransferases and the cytoskeleton
Methylation is a fundamental post-translational modification best understood as regulating chromatin structure and gene expression, yet there is emerging evidence that methylation also shapes cytoskeletal organization, regulating key processes such as mitosis and cell migration. Proteomic studies have revealed cytoskeletal protein methylation is widespread, however little is known about the enzymes responsible for these modifications, or their evolutionary relationship to other, better known substrates for methylation, such as chromatin. To address this question, we applied phylogenetic profiling across the complete repertoire of human methyltransferases to identify conserved functional relationships extending beyond chromatin. Unbiased clustering revealed extensive coevolution between methyltransferases and many components of the cytoskeleton, uncovering a previously unrecognized evolutionary network linking canonical chromatin regulatory enzymes to cellular structural systems. Evolutionary Trace analysis of the H3K36 methyltransferase family recovered known catalytic and regulatory domains while identifying additional evolutionarily constrained residues, suggesting previously unappreciated functional interfaces. Comparative analyses further distinguished deeply conserved methyltransferase–cytoskeletal relationships from those that emerged later during eukaryotic evolution, indicating that cytoskeletal methylation comprises both ancient and lineage-expanded regulatory programs. Leveraging these evolutionary signatures, we identified and experimentally validated a previously unrecognized association between the methyltransferase NSD3 and α-tubulin. Together, these findings reveal that methyltransferases traditionally viewed as chromatin regulators participate in an evolutionarily conserved network that coordinates nuclear and cytoskeletal functions. More broadly, they establish phylogenetic profiling as a powerful approach for discovering noncanonical activities of chromatin-associated enzymes and suggest that regulation of chromatin organization and cellular architecture evolved as interconnected processes.
- 22 April 2024
- Published by Springer Nature in Nature Microbiology
- Vol. 9 (5) , 1382-1392
Targeted accurate RNA consensus sequencing (tARC-seq) reveals mechanisms of replication error affecting SARS-CoV-2 divergence
RNA viruses, like SARS-CoV-2, depend on their RNA-dependent RNA polymerases (RdRp) for replication, which is error prone. Monitoring replication errors is crucial for understanding the virus’s evolution. Current methods lack the precision to detect rare de novo RNA mutations, particularly in low-input samples such as those from patients. Here we introduce a targeted accurate RNA consensus sequencing method (tARC-seq) to accurately determine the mutation frequency and types in SARS-CoV-2, both in cell culture and clinical samples. Our findings show an average of 2.68 × 10−5 de novo errors per cycle with a C > T bias that cannot be solely attributed to APOBEC editing. We identified hotspots and cold spots throughout the genome, correlating with high or low GC content, and pinpointed transcription regulatory sites as regions more susceptible to errors. tARC-seq captured template switching events including insertions, deletions and complex mutations. These insights shed light on the genetic diversity generation and evolutionary dynamics of SARS-CoV-2.
- 22 April 2024
- Published by Springer Nature in Nature Microbiology
- Vol. 9 (5) , 1382-1392
Targeted accurate RNA consensus sequencing (tARC-seq) reveals mechanisms of replication error affecting SARS-CoV-2 divergence
RNA viruses, like SARS-CoV-2, depend on their RNA-dependent RNA polymerases (RdRp) for replication, which is error prone. Monitoring replication errors is crucial for understanding the virus’s evolution. Current methods lack the precision to detect rare de novo RNA mutations, particularly in low-input samples such as those from patients. Here we introduce a targeted accurate RNA consensus sequencing method (tARC-seq) to accurately determine the mutation frequency and types in SARS-CoV-2, both in cell culture and clinical samples. Our findings show an average of 2.68 × 10−5 de novo errors per cycle with a C > T bias that cannot be solely attributed to APOBEC editing. We identified hotspots and cold spots throughout the genome, correlating with high or low GC content, and pinpointed transcription regulatory sites as regions more susceptible to errors. tARC-seq captured template switching events including insertions, deletions and complex mutations. These insights shed light on the genetic diversity generation and evolutionary dynamics of SARS-CoV-2.
- Open Access
- 31 July 2023
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 39 (8)
ShinyBioHEAT: an interactive shiny app to identify phenotype driver genes in E.coli and B.subtilis
In any population under selective pressure, a central challenge is to distinguish the genes that drive adaptation from others which, subject to population variation, harbor many neutral mutations de novo. We recently showed that such genes could be identified by supplementing information on mutational frequency with an evolutionary analysis of the likely functional impact of coding variants. This approach improved the discovery of driver genes in both lab-evolved and environmental Escherichia coli strains. To facilitate general adoption, we now developed ShinyBioHEAT, an R Shiny web-based application that enables identification of phenotype driving gene in two commonly used model bacteria, E.coli and Bacillus subtilis, with no specific computational skill requirements. ShinyBioHEAT not only supports transparent and interactive analysis of lab evolution data in E.coli and B.subtilis, but it also creates dynamic visualizations of mutational impact on protein structures, which add orthogonal checks on predicted drivers. Code for ShinyBioHEAT is available at https://github.com/LichtargeLab/ShinyBioHEAT. The Shiny application is additionally hosted at http://bioheat.lichtargelab.org/.
- 31 July 2023
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 39 (8)
Open AccessShinyBioHEAT: an interactive shiny app to identify phenotype driver genes in E.coli and B.subtilis
In any population under selective pressure, a central challenge is to distinguish the genes that drive adaptation from others which, subject to population variation, harbor many neutral mutations de novo. We recently showed that such genes could be identified by supplementing information on mutational frequency with an evolutionary analysis of the likely functional impact of coding variants. This approach improved the discovery of driver genes in both lab-evolved and environmental Escherichia coli strains. To facilitate general adoption, we now developed ShinyBioHEAT, an R Shiny web-based application that enables identification of phenotype driving gene in two commonly used model bacteria, E.coli and Bacillus subtilis, with no specific computational skill requirements. ShinyBioHEAT not only supports transparent and interactive analysis of lab evolution data in E.coli and B.subtilis, but it also creates dynamic visualizations of mutational impact on protein structures, which add orthogonal checks on predicted drivers. Code for ShinyBioHEAT is available at https://github.com/LichtargeLab/ShinyBioHEAT. The Shiny application is additionally hosted at http://bioheat.lichtargelab.org/.
- Open Access
- 7 June 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (7) , 104896
CovET: A covariation-evolutionary trace method that identifies protein structure–function modules
- 7 June 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (7) , 104896
Open AccessCovET: A covariation-evolutionary trace method that identifies protein structure–function modules
- Open Access
- 9 June 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-13
Evolutionary action of mutations reveals antimicrobial resistance genes in Escherichia coli
Since antibiotic development lags, we search for potential drug targets through directed evolution experiments. A challenge is that many resistance genes hide in a noisy mutational background as mutator clones emerge in the adaptive population. Here, to overcome this noise, we quantify the impact of mutations through evolutionary action (EA). After sequencing ciprofloxacin or colistin resistance strains grown under different mutational regimes, we find that an elevated sum of the evolutionary action of mutations in a gene identifies known resistance drivers. This EA integration approach also suggests new antibiotic resistance genes which are then shown to provide a fitness advantage in competition experiments. Moreover, EA integration analysis of clinical and environmental isolates of antibiotic resistant of E. coli identifies gene drivers of resistance where a standard approach fails. Together these results inform the genetic basis of de novo colistin resistance and support the robust discovery of phenotype-driving genes via the evolutionary action of genetic perturbations in fitness landscapes.
- 9 June 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-13
Open AccessEvolutionary action of mutations reveals antimicrobial resistance genes in Escherichia coli
Since antibiotic development lags, we search for potential drug targets through directed evolution experiments. A challenge is that many resistance genes hide in a noisy mutational background as mutator clones emerge in the adaptive population. Here, to overcome this noise, we quantify the impact of mutations through evolutionary action (EA). After sequencing ciprofloxacin or colistin resistance strains grown under different mutational regimes, we find that an elevated sum of the evolutionary action of mutations in a gene identifies known resistance drivers. This EA integration approach also suggests new antibiotic resistance genes which are then shown to provide a fitness advantage in competition experiments. Moreover, EA integration analysis of clinical and environmental isolates of antibiotic resistant of E. coli identifies gene drivers of resistance where a standard approach fails. Together these results inform the genetic basis of de novo colistin resistance and support the robust discovery of phenotype-driving genes via the evolutionary action of genetic perturbations in fitness landscapes.
- Open Access
- 27 May 2021
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 37 (22) , 4033-4040
Identification of evolutionarily stable functional and immunogenic sites across the SARS-CoV-2 proteome and greater coronavirus family
Since the first recognized case of COVID-19, more than 100 million people have been infected worldwide. Global efforts in drug and vaccine development to fight the disease have yielded vaccines and drug candidates to cure COVID-19. However, the spread of SARS-CoV-2 variants threatens the continued efficacy of these treatments. In order to address this, we interrogate the evolutionary history of the entire SARS-CoV-2 proteome to identify evolutionarily conserved functional sites that can inform the search for treatments with broader coverage across the coronavirus family. Combining coronavirus family sequence information with the mutations observed in the current COVID-19 outbreak, we systematically and comprehensively define evolutionarily stable sites that may provide useful drug and vaccine targets and which are less likely to be compromised by the emergence of new virus strains. Several experimentally validated effective drugs interact with these proposed target sites. In addition, the same evolutionary information can prioritize cross reactive antigens that are useful in directing multi-epitope vaccine strategies to illicit broadly neutralizing immune responses to the betacoronavirus family. Although the results are focused on SARS-CoV-2, these approaches stem from evolutionary principles that are agnostic to the organism or infective agent. The results of this work are made interactively available at http://cov.lichtargelab.org. Supplementary data are available at Bioinformatics online.
- 27 May 2021
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 37 (22) , 4033-4040
Open AccessIdentification of evolutionarily stable functional and immunogenic sites across the SARS-CoV-2 proteome and greater coronavirus family
Since the first recognized case of COVID-19, more than 100 million people have been infected worldwide. Global efforts in drug and vaccine development to fight the disease have yielded vaccines and drug candidates to cure COVID-19. However, the spread of SARS-CoV-2 variants threatens the continued efficacy of these treatments. In order to address this, we interrogate the evolutionary history of the entire SARS-CoV-2 proteome to identify evolutionarily conserved functional sites that can inform the search for treatments with broader coverage across the coronavirus family. Combining coronavirus family sequence information with the mutations observed in the current COVID-19 outbreak, we systematically and comprehensively define evolutionarily stable sites that may provide useful drug and vaccine targets and which are less likely to be compromised by the emergence of new virus strains. Several experimentally validated effective drugs interact with these proposed target sites. In addition, the same evolutionary information can prioritize cross reactive antigens that are useful in directing multi-epitope vaccine strategies to illicit broadly neutralizing immune responses to the betacoronavirus family. Although the results are focused on SARS-CoV-2, these approaches stem from evolutionary principles that are agnostic to the organism or infective agent. The results of this work are made interactively available at http://cov.lichtargelab.org. Supplementary data are available at Bioinformatics online.
- Open Access
- 15 February 2021
- Published by Springer Nature in Research Square
Identification of evolutionarily stable functional and immunogenic sites across the SARS-CoV-2 proteome and the greater coronavirus family
Since the first recognized case of COVID-19, more than 100 million people have been infected worldwide. Global efforts in drug and vaccine development to fight the disease have yielded vaccines and drug candidates to cure COVID-19. However, the spread of SARS-CoV-2 variants threatens the continued efficacy of these treatments. In order to address this, we interrogate the evolutionary history of the entire SARS-CoV-2 proteome to identify evolutionarily conserved functional sites that can inform the search for treatments with broader coverage across the coronavirus family. Combining this information with the mutations observed in the current COVID-19 outbreak, we systematically and comprehensively define evolutionarily stable sites that may provide useful drug and vaccine targets and which are less likely to be compromised by the emergence of new virus strains. Several experimentally-validated effective drugs interact with these proposed target sites. In addition, the same evolutionary information can prioritize cross reactive antigens that are useful in directing multi-epitope vaccine strategies to illicit broadly neutralizing immune responses to the betacoronavirus family. Although the results are focused on SARS-CoV-2, these approaches stem from evolutionary principles that are agnostic to the organism or infective agent.
- 15 February 2021
- Published by Springer Nature in Research Square
Open AccessIdentification of evolutionarily stable functional and immunogenic sites across the SARS-CoV-2 proteome and the greater coronavirus family
Since the first recognized case of COVID-19, more than 100 million people have been infected worldwide. Global efforts in drug and vaccine development to fight the disease have yielded vaccines and drug candidates to cure COVID-19. However, the spread of SARS-CoV-2 variants threatens the continued efficacy of these treatments. In order to address this, we interrogate the evolutionary history of the entire SARS-CoV-2 proteome to identify evolutionarily conserved functional sites that can inform the search for treatments with broader coverage across the coronavirus family. Combining this information with the mutations observed in the current COVID-19 outbreak, we systematically and comprehensively define evolutionarily stable sites that may provide useful drug and vaccine targets and which are less likely to be compromised by the emergence of new virus strains. Several experimentally-validated effective drugs interact with these proposed target sites. In addition, the same evolutionary information can prioritize cross reactive antigens that are useful in directing multi-epitope vaccine strategies to illicit broadly neutralizing immune responses to the betacoronavirus family. Although the results are focused on SARS-CoV-2, these approaches stem from evolutionary principles that are agnostic to the organism or infective agent.
- Open Access
- 8 June 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-10
CRISPR-FRT targets shared sites in a knock-out collection for off-the-shelf genome editing
CRISPR advances genome engineering by directing endonuclease sequence specificity with a guide RNA molecule (gRNA). For precisely targeting a gene for modification, each genetic construct requires a unique gRNA. By generating a gRNA against the flippase recognition target (FRT) site, a common genetic element shared by multiple genetic collections, CRISPR-FRT circumvents this design constraint to provide a broad platform for fast, scarless, off-the-shelf genome engineering.
- 8 June 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-10
Open AccessCRISPR-FRT targets shared sites in a knock-out collection for off-the-shelf genome editing
CRISPR advances genome engineering by directing endonuclease sequence specificity with a guide RNA molecule (gRNA). For precisely targeting a gene for modification, each genetic construct requires a unique gRNA. By generating a gRNA against the flippase recognition target (FRT) site, a common genetic element shared by multiple genetic collections, CRISPR-FRT circumvents this design constraint to provide a broad platform for fast, scarless, off-the-shelf genome engineering.
- Open Access
- 6 November 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (11) , e0187169
Structural basis of antifreeze activity of a bacterial multi-domain antifreeze protein
Antifreeze proteins (AFPs) enhance the survival of organisms inhabiting cold environments by affecting the formation and/or structure of ice. We report the crystal structure of the first multi-domain AFP that has been characterized. The two ice binding domains are structurally similar. Each consists of an irregular β-helix with a triangular cross-section and a long α-helix that runs parallel on one side of the β-helix. Both domains are stabilized by hydrophobic interactions. A flat plane on the same face of each domain’s β-helix was identified as the ice binding site. Mutating any of the smaller residues on the ice binding site to bulkier ones decreased the antifreeze activity. The bulky side chain of Leu174 in domain A sterically hinders the binding of water molecules to the protein backbone, partially explaining why antifreeze activity by domain A is inferior to that of domain B. Our data provide a molecular basis for understanding differences in antifreeze activity between the two domains of this protein and general insight on how structural differences in the ice-binding sites affect the activity of AFPs.
- 6 November 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (11) , e0187169
Open AccessStructural basis of antifreeze activity of a bacterial multi-domain antifreeze protein
Antifreeze proteins (AFPs) enhance the survival of organisms inhabiting cold environments by affecting the formation and/or structure of ice. We report the crystal structure of the first multi-domain AFP that has been characterized. The two ice binding domains are structurally similar. Each consists of an irregular β-helix with a triangular cross-section and a long α-helix that runs parallel on one side of the β-helix. Both domains are stabilized by hydrophobic interactions. A flat plane on the same face of each domain’s β-helix was identified as the ice binding site. Mutating any of the smaller residues on the ice binding site to bulkier ones decreased the antifreeze activity. The bulky side chain of Leu174 in domain A sterically hinders the binding of water molecules to the protein backbone, partially explaining why antifreeze activity by domain A is inferior to that of domain B. Our data provide a molecular basis for understanding differences in antifreeze activity between the two domains of this protein and general insight on how structural differences in the ice-binding sites affect the activity of AFPs.
- 8 July 2016
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 55 (28) , 3975-3983
Functional Analysis of a Bacterial Antifreeze Protein Indicates a Cooperative Effect between Its Two Ice-Binding Domains
Antifreeze proteins make up a class of ice-binding proteins (IBPs) that are possessed and expressed by certain cold-adapted organisms to enhance their freezing tolerance. Here we report the biophysical and functional characterization of an IBP discovered in a bacterium recovered from a deep glacial ice core drilled at Vostok Station, Antarctica (IBPv). Our study showed that the recombinant protein rIBPv exhibited a thermal hysteresis of 2 °C at concentrations of >50 μM, effectively inhibited ice recrystallization, and enhanced bacterial viability during freeze–thaw cycling. Circular dichroism scans indicated that rIBPv mainly consists of β strands, and its denaturing temperature was 53.5 °C. Multiple-sequence alignment of homologous IBPs predicted that IBPv contains two ice-binding domains, a feature unique among known IBPs. To examine functional differences between the IBPv domains, each domain was cloned, expressed, and purified. The second domain (domain B) expressed greater ice binding activity. Data from thermal hysteresis and gel filtration assays supported the idea that the two domains cooperate to achieve a higher ice binding effect by forming heterodimers. However, physical linkage of the domains was not required for this effect.
- 8 July 2016
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 55 (28) , 3975-3983
Functional Analysis of a Bacterial Antifreeze Protein Indicates a Cooperative Effect between Its Two Ice-Binding Domains
Antifreeze proteins make up a class of ice-binding proteins (IBPs) that are possessed and expressed by certain cold-adapted organisms to enhance their freezing tolerance. Here we report the biophysical and functional characterization of an IBP discovered in a bacterium recovered from a deep glacial ice core drilled at Vostok Station, Antarctica (IBPv). Our study showed that the recombinant protein rIBPv exhibited a thermal hysteresis of 2 °C at concentrations of >50 μM, effectively inhibited ice recrystallization, and enhanced bacterial viability during freeze–thaw cycling. Circular dichroism scans indicated that rIBPv mainly consists of β strands, and its denaturing temperature was 53.5 °C. Multiple-sequence alignment of homologous IBPs predicted that IBPv contains two ice-binding domains, a feature unique among known IBPs. To examine functional differences between the IBPv domains, each domain was cloned, expressed, and purified. The second domain (domain B) expressed greater ice binding activity. Data from thermal hysteresis and gel filtration assays supported the idea that the two domains cooperate to achieve a higher ice binding effect by forming heterodimers. However, physical linkage of the domains was not required for this effect.